Upcoming fda approval stocks

**Conclusion 🏁🚀** A string of FDA decisions—spanning from late October to early November—will soon determine the next leg of several biotech and pharma stories. Among them, **GSK (GSK), Merck (MRK), Syndax (SNDX) and Arrowhead (ARWR)** stand out as the most proximate catalysts, while **Replimune (REPL)** and **Myosin Therapeutics (MYOS)** offer longer-dated—but equally headline-sensitive—regulatory windows. Positioning ahead of time, with disciplined risk controls, can turn these binary events into opportunities rather than sources of anxiety. 🌟📈 --- ### 1. Near-Term FDA Dates (Next 30 Days) ⏳📅 The following four tickers all have FDA review dates within the next month, creating a compressed window for price discovery. Drugs with FDA Review Date in the next 30 days |code|market_code|stock code|stock name|Last Price|Last Change|Drug Name|Indication|FDA Approval Status|FDA Review Date| |---|---|---|---|---|---|---|---|---|---| |GSK|169|GSK.N|GSK|44.26|0.728266|Blenrep combinations (BVd & BPd)|Multiple myeloma|Pending|20251023| |MRK|169|MRK.N|Merck|87.7|0.091303|WINREVAIR (sotatercept-csrk)|Pulmonary arterial hypertension|Pending|20251025| |SNDX|185|SNDX.O|Syndax|15.1|-0.657895|Revuforj (revumenib) (SNDX-5613)|R/R mNPM1 Acute Myeloid Leukemia|Pending|20251025| |ARWR|185|ARWR.O|Arrowhead Pharmaceuticals|37.64|-1.025506|Plozasiran (ARO-APOC3)|Familial chylomicronemia syndrome|Pending|20251118| | Ticker | Drug / Device | Target Indication | Status | Key Takeaway | |--------|---------------|-------------------|--------|--------------| | **GSK** | Blenrep (BVd + BPd) | Multiple myeloma | Pending | CAR-T backbone; competitive vs. Kymriah/Yescarta | | **MRK** | WINREVAIR (sotatercept-csrk) | Pulmonary arterial hypertension | Pending | First-in-class sTropomyosin receptor kinase (sTRK) inhibitor | | **SNDX** | Revuforj (revumenib) | R/R mNPM1 AML | Pending | First-in-class menaquinone reductase inhibitor | | **ARWR** | Plozasiran (ARO-APOC3) | Familial chylomicronemia | Pending | First siRNA therapy for orphan lipoproteinosis | 😊 *Insight*: Because these dates are so close, liquidity can evaporate quickly—use limit orders and be prepared for ±15-25 % swings on news. --- ### 2. Broader Q4 FDA Calendar 🗓️✨ Expanding the lens to October–December 2025 reveals an even richer tapestry of potential catalysts, including several “larger-cap” names that often attract institutional flows. Public companies with FDA PDUFA dates October 2025 to December 2025 |code|market_code|stock code|stock name|Last Price|Last Change|Drug Name|Indication|FDA Approval Status|FDA Approval Event Type|FDA Review Date| |---|---|---|---|---|---|---|---|---|---|---| |GKOS|169|GKOS.N|Glaukos|76.64|1.001581|Epioxa (Epi-on)|Keratoconus|Approved|PDUFA Date|20251020| |GSK|169|GSK.N|GSK|44.26|0.728266|Blenrep combinations (BVd & BPd)|Multiple myeloma|Pending|PDUFA Date|20251023| |FBIOP|186|FBIOP.O|Fortress Biotech Pref A|6.77|0.146448|CUTX-101 (Copper Histidinate)|Menkes Disease , Blood cancer|Complete Response Letter|PDUFA Date|20251001| |MRK|169|MRK.N|Merck|87.7|0.091303|WINREVAIR (sotatercept-csrk)|Pulmonary arterial hypertension|Pending|PDUFA Date|20251025| |SNDX|185|SNDX.O|Syndax|15.1|-0.657895|Revuforj (revumenib) (SNDX-5613)|R/R mNPM1 Acute Myeloid Leukemia|Pending|PDUFA Date|20251025| |ARWR|185|ARWR.O|Arrowhead Pharmaceuticals|37.64|-1.025506|Plozasiran (ARO-APOC3)|Familial chylomicronemia syndrome|Pending|PDUFA Date|20251118| |AMGN|185|AMGN.O|Amgen|295.91|-1.7367339999999998|TEZSPIRE|Chronic rhinosinusitis with nasal polyps|Approved|PDUFA Date|20251017| |ARQT|185|ARQT.O|Arcutis|19.79|-4.118217|ZORYVE (ARQ-151) topical roflumilast cream (PDE4 Inhibitor)|Atopic dermatitis|Pending|PDUFA Date|20251013| |ARQT|185|ARQT.O|Arcutis|19.79|-4.118217|ZORYVE (ARQ-151) topical roflumilast cream|Atopic dermatitis|Approved|PDUFA Date|20251006| |FBIO|186|FBIO.O|Fortress Biotech|2.52|-9.025271|CUTX-101 (Copper Histidinate)|Menkes Disease , Blood cancer|Complete Response Letter|PDUFA Date|20251001| Key observations 📊 1. **Arcutis (ARQT)**: Topical roflumilast for atopic dermatitis—smaller float, huge binary move potential. 2. **Amgen (AMGN)**: Tezspire for sinusitis—biosimilar dynamics could temper enthusiasm. 3. **Fortress Biotech (FBIO/FBIO) & Pref A (FBIOP)**: Copper histidinate for Menkes disease—both received Complete Response Letters, highlighting how quickly hopes can fade. --- ### 3. Watch-List: Micro-Cap Catalysts 🔍🧬 Micro-caps can swing furthest on FDA news, but they also carry the highest risk of cash burn. SNDX is the clearest example today. Biotechnology stocks with upcoming FDA decisions |code|market_code|stock code|stock name|Last Price|Last Change|GICS Industry|Drug Name|Indication|FDA Approval Status|FDA Review Date| |---|---|---|---|---|---|---|---|---|---|---| |SNDX|185|SNDX.O|Syndax|15.1|-0.657895|Biotechnology|Revuforj (revumenib) (SNDX-5613)|R/R mNPM1 Acute Myeloid Leukemia|Pending|20251025| Risk checklist ⚠️ • **Runway**: Do management or investors have sufficient cash to fund trials/post-approval launch? • **Label Restraints**: REMS or REMS-like requirements can limit uptake despite approval. • **Market Size**: Even a “yes” may not translate to blockbuster sales if patient pools are tiny. --- ### 4. Longer-Dated but Equally Volatile 🕰️⚡ • **Replimune (REPL)**: FDA accepted resubmission for RP1 + nivolumab; PDUFA set for **April 10, 2026**. Positive feedback from the Type A meeting offers cautious optimism, yet the path remains uncertain. • **Myosin Therapeutics (MYOS)**: Fast-track designation for MT-125 in glioblastoma gives it a potential priority review window. Still, Phase 1/2 data are early, and GBM prognosis is grim. --- ### 5. Strategic Playbook 🎯🛡️ 1. **Hedge the Binary**: Protective puts or short-dated straddles can cap downside while preserving upside optionality. 2. **Staggered Entries**: For large-caps (GSK, MRK), use limit orders around the decision window; for micro-caps (SNDX, ARWR), consider scaling in before the catalyst to avoid missing the move. 3. **Monitor Cash**: Keep an eye on balance-sheet strength—biotechs that burn cash rapidly face higher bankruptcy risk if a “no” arrives. 4. **Narrative Pairing**: Pair longs in successful tickers with shorts in failed ones (where thesis permits) to isolate event risk. --- ### 6. Bottom Line 🌈 Q4 2025 is shaping up as a **“make-or-break” quarter for biotech equity**. By mapping the exact FDA dates, sizing positions prudently, and employing tactical hedges, investors can transform regulatory uncertainty into a structured opportunity. Stay nimble, manage cash flow, and may the odds be ever in your favor! 🤞📊